Literature DB >> 1911114

Recurrent primary disease and de novo nephritis following renal transplantation.

J S Cameron1.   

Abstract

Recurrent or de novo diseases account for only 5% of graft failure in children, but have much to teach us about mechanisms. In children, almost the only metabolic disease with recurrence is type I hyperoxaluria, in which the poor long-term results of isolated renal transplantation make combined liver and renal transplantation, or even prophylactic liver transplantation before renal failure the preferable alternatives. While many forms of nephritis may show histological recurrence in allografts, it is notable that in many patients this is accompanied by no clinical manifestations or only mild disease: this is particularly so in mesangiocapillary glomerulonephritis (MCGN) type II. IgA-associated nephropathy and Henoch-Schönlein purpura. However focal segmental glomerulosclerosis and MCGN type I recur with sufficient frequency and severity to deter the use of living donors unless there is no alternative. The same is true of haemolytic-uraemic syndromes. As many as 10% of paediatric grafts may show de novo membranous nephropathy, but in the majority this is mild or not clinically evident. In contrast, the rare anti-glomerular basement membrane nephritis affecting some patients with Alport's syndrome usually results in graft failure, but occurs in only a minority of recipients with the syndrome. For all types of disease in allografts, risk factors for recurrence are poorly worked out, and attempts at treatment generally ineffective.

Entities:  

Mesh:

Year:  1991        PMID: 1911114     DOI: 10.1007/bf01453669

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.714


  78 in total

1.  Kidney transplantation in primary oxalosis: data from the EDTA Registry.

Authors:  M Broyer; F P Brunner; H Brynger; S R Dykes; J H Ehrich; W Fassbinder; W Geerlings; G Rizzoni; N H Selwood; G Tufveson
Journal:  Nephrol Dial Transplant       Date:  1990       Impact factor: 5.992

2.  Ciclosporin-induced partial and transient improvement of nephrotic syndrome in recurrent focal segmental glomerulosclerosis.

Authors:  J M Morales; A Andres; C Prieto; M Praga; V Gutierrez Millet; J L Rodicio
Journal:  Nephron       Date:  1989       Impact factor: 2.847

3.  The incidence of membranoproliferative glomerulonephritis in renal allografts.

Authors:  M J Moritz; J F Burke; B E Jarrell; R A Carabasi
Journal:  Transplant Proc       Date:  1987-02       Impact factor: 1.066

Review 4.  Glomerulonephritis in renal transplants.

Authors:  J S Cameron
Journal:  Transplantation       Date:  1982-11       Impact factor: 4.939

5.  Absence of nephritogenic GBM antigen(s) in some patients with hereditary nephritis.

Authors:  R C McCoy; H K Johnson; W J Stone; C B Wilson
Journal:  Kidney Int       Date:  1982-04       Impact factor: 10.612

6.  Glomerulonephritis in renal transplantation.

Authors:  A Vangelista; G M Frascà; D Martella; V Bonomini
Journal:  Nephrol Dial Transplant       Date:  1990       Impact factor: 5.992

7.  Post-transplantation outcome of patients with hemolytic-uremic syndrome: update.

Authors:  D Hébert; E M Kim; R K Sibley; M S Mauer
Journal:  Pediatr Nephrol       Date:  1991-01       Impact factor: 3.714

8.  Demonstration of a passive Heymann nephritis-like mechanism in a human kidney transplant.

Authors:  M Zanetti; C Mandet; A Duboust; J Bedrossian; J Bariety
Journal:  Clin Nephrol       Date:  1981-05       Impact factor: 0.975

9.  De novo and recurrent membranous glomerulopathy following kidney transplantation.

Authors:  B E Berger; F Vincenti; C Biava; W J Amend; N Feduska; O Salvatierra
Journal:  Transplantation       Date:  1983-04       Impact factor: 4.939

10.  Involvement of renal allograft by Fabry's disease.

Authors:  S Popli; Z V Molnar; D J Leehey; J T Daugirdas; D A Roth; M B Adams; J C Cheng; T S Ing
Journal:  Am J Nephrol       Date:  1987       Impact factor: 3.754

View more
  12 in total

1.  The molecular genetics of Alport syndrome: report of two workshops.

Authors:  F Flinter; M Bobrow
Journal:  J Med Genet       Date:  1992-05       Impact factor: 6.318

Review 2.  Living donor kidney transplantation in patients with hereditary nephropathies.

Authors:  Patrick Niaudet
Journal:  Nat Rev Nephrol       Date:  2010-09-28       Impact factor: 28.314

3.  Focal segmental glomerulosclerosis relapse after transplantation: treatment with high cyclosporine doses and a short plasmaphaeresis course.

Authors:  A Delucchi; F Cano; E Rodriguez; E Wolff
Journal:  Pediatr Nephrol       Date:  1994-12       Impact factor: 3.714

4.  Acute post-streptococcal glomerulonephritis in a renal allograft.

Authors:  J M Sorof; N Weidner; D Potter; A A Portale
Journal:  Pediatr Nephrol       Date:  1995-06       Impact factor: 3.714

Review 5.  Glomerular disease of transplanted kidneys.

Authors:  U Frei
Journal:  Clin Investig       Date:  1993-10

Review 6.  Renal transplantation in infants and children.

Authors:  A Moudgil; S C Jordan
Journal:  Indian J Pediatr       Date:  1999 Mar-Apr       Impact factor: 1.967

7.  Recurrent nephrotic syndrome after transplantation: early treatment with plasmaphaeresis and cyclophosphamide.

Authors:  P Cochat; A Kassir; S Colon; C Glastre; B Tourniaire; B Parchoux; X Martin; L David
Journal:  Pediatr Nephrol       Date:  1993-02       Impact factor: 3.714

Review 8.  Non-immunological risk factors in paediatric renal transplantation.

Authors:  M F Gagnadoux; P Niaudet; M Broyer
Journal:  Pediatr Nephrol       Date:  1993-02       Impact factor: 3.714

Review 9.  Mild phenotypic manifestation of a 7p15.3p21.2 deletion.

Authors:  C Wang; S Maynard; T W Glover; L G Biesecker
Journal:  J Med Genet       Date:  1993-07       Impact factor: 6.318

10.  Prompt remission of post-renal transplant nephrotic syndrome with high-dose cyclosporine.

Authors:  R N Srivastava; A Kalia; L B Travis; S C Diven; K K Gugliuzza; S Rajaraman
Journal:  Pediatr Nephrol       Date:  1994-02       Impact factor: 3.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.